{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T18:53:16Z","timestamp":1789325596684,"version":"build-2803163510"},"reference-count":56,"publisher":"American Society for Microbiology","issue":"12","license":[{"start":{"date-parts":[[2010,12,1]],"date-time":"2010-12-01T00:00:00Z","timestamp":1291161600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Clin Vaccine Immunol"],"published-print":{"date-parts":[[2010,12]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>Norwalk virus (NV) is an enteric pathogen from the genus<jats:italic>Norovirus<\/jats:italic>and a major cause of nonbacterial gastroenteritis in humans. NV virus-like particles (VLPs) are known to elicit systemic and mucosal immune responses when delivered nasally; however, the correlates of immune protection are unknown, and codelivery with a safe and immunogenic mucosal adjuvant may enhance protective anti-NV immune responses. Resiquimod (R848), an imidazoquinoline-based Toll-like receptor 7 and\/or 8 (TLR7\/8) agonist, is being evaluated as an adjuvant in FDA-approved clinical vaccine trials. As such, we evaluated the adjuvant activity of two imidazoquinoline-based TLR7 and TLR7\/8 agonists when codelivered intranasally with plant-derived NV VLPs. We also compared the activity of these agonists to the gold standard mucosal adjuvant, cholera toxin (CT). Our results indicate that codelivery with the TLR7 agonist, gardiquimod (GARD), induces NV VLP-specific serum IgG and IgG isotype responses and mucosal IgA responses in the gastrointestinal, respiratory, and reproductive tracts that are superior to those induced by R848 and comparable to those induced by the mucosal adjuvant CT. This study supports the continued investigation of GARD as a mucosal adjuvant for NV VLPs and possible use for other VLP-based vaccines for which immune responses at distal mucosal sites (e.g., respiratory and reproductive tracts) are desired.<\/jats:p>","DOI":"10.1128\/cvi.00230-10","type":"journal-article","created":{"date-parts":[[2010,10,21]],"date-time":"2010-10-21T02:47:17Z","timestamp":1287629237000},"page":"1850-1858","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":46,"title":["An Intranasally Delivered Toll-Like Receptor 7 Agonist Elicits Robust Systemic and Mucosal Responses to Norwalk Virus-Like Particles"],"prefix":"10.1128","volume":"17","author":[{"given":"Lissette S.","family":"Velasquez","sequence":"first","affiliation":[{"name":"Center for Infectious Diseases and Vaccinology, Biodesign Institute, Arizona State University, Tempe, Arizona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brooke E.","family":"Hjelm","sequence":"additional","affiliation":[{"name":"School of Life Sciences, Arizona State University, Tempe, Arizona"},{"name":"Translational Genomics Research Institute, Phoenix, Arizona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles J.","family":"Arntzen","sequence":"additional","affiliation":[{"name":"Center for Infectious Diseases and Vaccinology, Biodesign Institute, Arizona State University, Tempe, Arizona"},{"name":"School of Life Sciences, Arizona State University, Tempe, Arizona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa M.","family":"Herbst-Kralovetz","sequence":"additional","affiliation":[{"name":"Center for Infectious Diseases and Vaccinology, Biodesign Institute, Arizona State University, Tempe, Arizona"},{"name":"Department of Basic Medical Sciences, University of Arizona College of Medicine-Phoenix, Phoenix, Arizona"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1038\/35021228","volume":"406","year":"2000","unstructured":"Aderem, A., and R. J. Ulevitch. 2000. Toll-like receptors in the induction of the innate immune response. Nature406:782-787.","journal-title":"Nature"},{"key":"e_1_3_2_3_2","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1006\/cimm.1999.1555","volume":"197","year":"1999","unstructured":"Ahonen, C. L., S. J. Gibson, R. M. Smith, L. K. Pederson, J. M. Lindh, M. A. Tomai, and J. P. Vasilakos. 1999. Dendritic cell maturation and subsequent enhanced T-cell stimulation induced with the novel synthetic immune response modifier R-848. Cell. Immunol.197:62-72.","journal-title":"Cell. Immunol."},{"key":"e_1_3_2_4_2","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0165-2478(02)00228-6","volume":"85","year":"2003","unstructured":"Akira, S., and H. Hemmi. 2003. Recognition of pathogen-associated molecular patterns by TLR family. Immunol. Lett.85:85-95.","journal-title":"Immunol. Lett."},{"key":"e_1_3_2_5_2","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1084\/jem.20041930","volume":"201","year":"2005","unstructured":"Asselin-Paturel, C., G. Brizard, K. Chemin, A. Boonstra, A. O'Garra, A. Vicari, and G. Trinchieri. 2005. Type I interferon dependence of plasmacytoid dendritic cell activation and migration. J. Exp. Med.201:1157-1167.","journal-title":"J. Exp. Med."},{"key":"e_1_3_2_6_2","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1016\/j.vaccine.2009.03.018","volume":"27","year":"2009","unstructured":"Baldwin, S. L., S. Bertholet, M. Kahn, I. Zharkikh, G. C. Ireton, T. S. Vedvick, S. G. Reed, and R. N. Coler. 2009. Intradermal immunization improves protective efficacy of a novel TB vaccine candidate. Vaccine27:3063-3071.","journal-title":"Vaccine"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.72.2.1345-1353.1998"},{"key":"e_1_3_2_8_2","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.smim.2007.01.003","volume":"19","year":"2007","unstructured":"Barton, G. M. 2007. Viral recognition by Toll-like receptors. Semin. Immunol.19:33-40.","journal-title":"Semin. Immunol."},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.78.15.7867-7873.2004"},{"key":"e_1_3_2_10_2","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/j.1600-065X.2008.00680.x","volume":"225","year":"2008","unstructured":"Donaldson, E. F., L. C. Lindesmith, A. D. Lobue, and R. S. Baric. 2008. Norovirus pathogenesis: mechanisms of persistence and immune evasion in human populations. Immunol. Rev.225:190-211.","journal-title":"Immunol. Rev."},{"key":"e_1_3_2_11_2","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.4049\/jimmunol.171.3.1156","volume":"171","year":"2003","unstructured":"Doxsee, C. L., T. R. Riter, M. J. Reiter, S. J. Gibson, J. P. Vasilakos, and R. M. Kedl. 2003. The immune response modifier and Toll-like receptor 7 agonist S-27609 selectively induces IL-12 and TNF-alpha production in CD11c+CD11b+CD8- dendritic cells. J. Immunol.171:1156-1163.","journal-title":"J. Immunol."},{"key":"e_1_3_2_12_2","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1001\/archderm.134.1.25","volume":"134","year":"1998","unstructured":"Edwards, L., A. Ferenczy, L. Eron, D. Baker, M. L. Owens, T. L. Fox, A. J. Hougham, K. A. Schmitt, and the HPV Study Group. 1998. Self-administered topical 5% imiquimod cream for external anogenital warts. Arch. Dermatol.134:25-30.","journal-title":"Arch. Dermatol."},{"key":"e_1_3_2_13_2","doi-asserted-by":"crossref","first-page":"S367","DOI":"10.1086\/315579","volume":"181","year":"2000","unstructured":"Estes, M. K., J. M. Ball, R. A. Guerrero, A. R. Opekun, M. A. Gilger, S. S. Pacheco, and D. Y. Graham. 2000. Norwalk virus vaccines: challenges and progress. J. Infect. Dis.181(Suppl. 2):S367-S373.","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_14_2","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1086\/597071","volume":"199","year":"2009","unstructured":"Garland, S. M., M. Steben, H. L. Sings, M. James, S. Lu, R. Railkar, E. Barr, R. M. Haupt, and E. A. Joura. 2009. Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. J. Infect. Dis.199:805-814.","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_15_2","doi-asserted-by":"crossref","first-page":"5937","DOI":"10.1016\/j.vaccine.2006.06.005","volume":"24","year":"2006","unstructured":"Giannini, S. L., E. Hanon, P. Moris, M. Van Mechelen, S. Morel, F. Dessy, M. A. Fourneau, B. Colau, J. Suzich, G. Losonksy, M. T. Martin, G. Dubin, and M. A. Wettendorff. 2006. Enhanced humoral and memory B cellular immunity using HPV16\/18 L1 VLP vaccine formulated with the MPL\/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine24:5937-5949.","journal-title":"Vaccine"},{"key":"e_1_3_2_16_2","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1600-0897.2007.00558.x","volume":"59","year":"2008","unstructured":"Gill, N., E. J. Davies, and A. A. Ashkar. 2008. The role of Toll-like receptor ligands\/agonists in protection against genital HSV-2 infection. Am. J. Reprod. Immunol.59:35-43.","journal-title":"Am. J. Reprod. Immunol."},{"key":"e_1_3_2_17_2","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1056\/NEJMra0804575","volume":"361","year":"2009","unstructured":"Glass, R. I., U. D. Parashar, and M. K. Estes. 2009. Norovirus gastroenteritis. N. Engl. J. Med.361:1776-1785.","journal-title":"N. Engl. J. Med."},{"key":"e_1_3_2_18_2","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.4049\/jimmunol.174.3.1259","volume":"174","year":"2005","unstructured":"Gorden, K. B., K. S. Gorski, S. J. Gibson, R. M. Kedl, W. C. Kieper, X. Qiu, M. A. Tomai, S. S. Alkan, and J. P. Vasilakos. 2005. Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8. J. Immunol.174:1259-1268.","journal-title":"J. Immunol."},{"key":"e_1_3_2_19_2","doi-asserted-by":"crossref","first-page":"6584","DOI":"10.4049\/jimmunol.177.10.6584","volume":"177","year":"2006","unstructured":"Gorden, K. K., X. X. Qiu, C. C. Binsfeld, J. P. Vasilakos, and S. S. Alkan. 2006. Activation of murine TLR8 by a combination of imidazoquinoline immune response modifiers and polyT oligodeoxynucleotides. J. Immunol.177:6584-6587.","journal-title":"J. Immunol."},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.31.8.2185-2191.1993"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.75.20.9713-9722.2001"},{"key":"e_1_3_2_22_2","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/ni758","volume":"3","year":"2002","unstructured":"Hemmi, H., T. Kaisho, O. Takeuchi, S. Sato, H. Sanjo, K. Hoshino, T. Horiuchi, H. Tomizawa, K. Takeda, and S. Akira. 2002. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat. Immunol.3:196-200.","journal-title":"Nat. Immunol."},{"key":"e_1_3_2_23_2","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1586\/erv.09.163","volume":"9","year":"2010","unstructured":"Herbst-Kralovetz, M., H. S. Mason, and Q. Chen. 2010. Norwalk virus-like particles as vaccines. Expert Rev. Vaccines9:299-307.","journal-title":"Expert Rev. Vaccines"},{"key":"e_1_3_2_24_2","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.imlet.2004.11.009","volume":"97","year":"2005","unstructured":"Holmgren, J., J. Adamsson, F. Anjuere, J. Clemens, C. Czerkinsky, K. Eriksson, C. F. Flach, A. George-Chandy, A. M. Harandi, M. Lebens, T. Lehner, M. Lindblad, E. Nygren, S. Raghavan, J. Sanchez, M. Stanford, J. B. Sun, A. M. Svennerholm, and S. Tengvall. 2005. Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA. Immunol. Lett.97:181-188.","journal-title":"Immunol. Lett."},{"key":"e_1_3_2_25_2","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1586\/14760584.2.2.205","volume":"2","year":"2003","unstructured":"Holmgren, J., A. M. Harandi, and C. Czerkinsky. 2003. Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA. Expert Rev. Vaccines2:205-217.","journal-title":"Expert Rev. Vaccines"},{"key":"e_1_3_2_26_2","doi-asserted-by":"crossref","first-page":"4531","DOI":"10.4049\/jimmunol.168.9.4531","volume":"168","year":"2002","unstructured":"Hornung, V., S. Rothenfusser, S. Britsch, A. Krug, B. Jahrsdorfer, T. Giese, S. Endres, and G. Hartmann. 2002. Quantitative expression of Toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J. Immunol.168:4531-4537.","journal-title":"J. Immunol."},{"key":"e_1_3_2_27_2","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/j.vaccine.2004.11.017","volume":"23","year":"2005","unstructured":"Huang, Z., G. Elkin, B. J. Maloney, N. Beuhner, C. J. Arntzen, Y. Thanavala, and H. S. Mason. 2005. Virus-like particle expression and assembly in plants: hepatitis B and Norwalk viruses. Vaccine23:1851-1858.","journal-title":"Vaccine"},{"key":"e_1_3_2_28_2","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.1002\/1521-4141(200111)31:11<3388::AID-IMMU3388>3.0.CO;2-Q","volume":"31","year":"2001","unstructured":"Jarrossay, D., G. Napolitani, M. Colonna, F. Sallusto, and A. Lanzavecchia. 2001. Specialization and complementarity in microbial molecule recognition by human myeloid and plasmacytoid dendritic cells. Eur. J. Immunol.31:3388-3393.","journal-title":"Eur. J. Immunol."},{"key":"e_1_3_2_29_2","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/nm1589","volume":"13","year":"2007","unstructured":"Kanzler, H., F. J. Barrat, E. M. Hessel, and R. L. Coffman. 2007. Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat. Med.13:552-559.","journal-title":"Nat. Med."},{"key":"e_1_3_2_30_2","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1586\/14760584.5.3.365","volume":"5","year":"2006","unstructured":"Klinman, D. M. 2006. CpG oligonucleotides accelerate and boost the immune response elicited by AVA, the licensed anthrax vaccine. Expert Rev. Vaccines5:365-369.","journal-title":"Expert Rev. Vaccines"},{"key":"e_1_3_2_31_2","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.jaad.2003.12.010","volume":"50","year":"2004","unstructured":"Lebwohl, M., S. Dinehart, D. Whiting, P. K. Lee, N. Tawfik, J. Jorizzo, J. H. Lee, and T. L. Fox. 2004. Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials. J. Am. Acad. Dermatol.50:714-721.","journal-title":"J. Am. Acad. Dermatol."},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01650-08"},{"key":"e_1_3_2_33_2","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/j.1365-2567.2009.03237.x","volume":"130","year":"2010","unstructured":"Ma, Y., L. Poisson, G. Sanchez-Schmitz, S. Pawar, C. Qu, G. J. Randolph, W. L. Warren, E. M. Mishkin, and R. G. Higbee. 2010. Assessing the immunopotency of Toll-like receptor agonists in an in vitro tissue-engineered immunological model. Immunology130:374-387.","journal-title":"Immunology"},{"key":"e_1_3_2_34_2","doi-asserted-by":"crossref","first-page":"5335","DOI":"10.1073\/pnas.93.11.5335","volume":"93","year":"1996","unstructured":"Mason, H. S., J. M. Ball, J. J. Shi, X. Jiang, M. K. Estes, and C. J. Arntzen. 1996. Expression of Norwalk virus capsid protein in transgenic tobacco and potato and its oral immunogenicity in mice. Proc. Natl. Acad. Sci. U. S. A.93:5335-5340.","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"e_1_3_2_35_2","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/307178a0","volume":"307","year":"1984","unstructured":"McAleer, W. J., E. B. Buynak, R. Z. Maigetter, D. E. Wampler, W. J. Miller, and M. R. Hilleman. 1984. Human hepatitis B vaccine from recombinant yeast. Nature307:178-180.","journal-title":"Nature"},{"key":"e_1_3_2_36_2","first-page":"5","volume":"175","year":"2005","unstructured":"Mosmann, T. R., H. Cherwinski, M. W. Bond, M. A. Giedlin, and R. L. Coffman. 2005. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J. Immunol.175:5-14.","journal-title":"J. Immunol."},{"key":"e_1_3_2_37_2","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1146\/annurev.iy.07.040189.001045","volume":"7","year":"1989","unstructured":"Mosmann, T. R., and R. L. Coffman. 1989. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu. Rev. Immunol.7:145-173.","journal-title":"Annu. Rev. Immunol."},{"key":"e_1_3_2_38_2","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa030595","volume":"350","year":"2004","unstructured":"Mutsch, M., W. Zhou, P. Rhodes, M. Bopp, R. T. Chen, T. Linder, C. Spyr, and R. Steffen. 2004. Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. N. Engl. J. Med.350:896-903.","journal-title":"N. Engl. J. Med."},{"key":"e_1_3_2_39_2","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1016\/j.vaccine.2004.01.037","volume":"22","year":"2004","unstructured":"Otero, M., S. A. Calarota, B. Felber, D. Laddy, G. Pavlakis, J. D. Boyer, and D. B. Weiner. 2004. Resiquimod is a modest adjuvant for HIV-1 gag-based genetic immunization in a mouse model. Vaccine22:1782-1790.","journal-title":"Vaccine"},{"key":"e_1_3_2_40_2","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1016\/S0140-6736(07)60946-5","volume":"369","year":"2007","unstructured":"Paavonen, J., D. Jenkins, F. X. Bosch, P. Naud, J. Salmeron, C. M. Wheeler, S. N. Chow, D. L. Apter, H. C. Kitchener, X. Castellsague, N. S. de Carvalho, S. R. Skinner, D. M. Harper, J. A. Hedrick, U. Jaisamrarn, G. A. Limson, M. Dionne, W. Quint, B. Spiessens, P. Peeters, F. Struyf, S. L. Wieting, M. O. Lehtinen, and G. Dubin. 2007. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet369:2161-2170.","journal-title":"Lancet"},{"key":"e_1_3_2_41_2","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.3201\/eid1408.071114","volume":"14","year":"2008","unstructured":"Patel, M. M., M. A. Widdowson, R. I. Glass, K. Akazawa, J. Vinje, and U. D. Parashar. 2008. Systematic literature review of role of noroviruses in sporadic gastroenteritis. Emerg. Infect. Dis.14:1224-1231.","journal-title":"Emerg. Infect. Dis."},{"key":"e_1_3_2_42_2","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1126\/science.1113401","volume":"309","year":"2005","unstructured":"Peng, G., Z. Guo, Y. Kiniwa, K. S. Voo, W. Peng, T. Fu, D. Y. Wang, Y. Li, H. Y. Wang, and R. F. Wang. 2005. Toll-like receptor 8-mediated reversal of CD4+ regulatory T cell function. Science309:1380-1384.","journal-title":"Science"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2006.02.019"},{"key":"e_1_3_2_44_2","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1111\/j.1365-2222.2004.02023.x","volume":"34","year":"2004","unstructured":"Quarcoo, D., S. Weixler, R. A. Joachim, P. Stock, T. Kallinich, B. Ahrens, and E. Hamelmann. 2004. Resiquimod, a new immune response modifier from the family of imidazoquinolinamines, inhibits allergen-induced Th2 responses, airway inflammation and airway hyper-reactivity in mice. Clin. Exp. Allergy34:1314-1320.","journal-title":"Clin. Exp. Allergy"},{"key":"e_1_3_2_45_2","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1182\/blood-2009-08-238543","volume":"115","year":"2010","unstructured":"Rajagopal, D., C. Paturel, Y. Morel, S. Uematsu, S. Akira, and S. S. Diebold. 2010. Plasmacytoid dendritic cell-derived type I interferon is crucial for the adjuvant activity of Toll-like receptor 7 agonists. Blood115:1949-1957.","journal-title":"Blood"},{"key":"e_1_3_2_46_2","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1016\/j.vaccine.2008.01.053","volume":"26","year":"2008","unstructured":"Santi, L., L. Batchelor, Z. Huang, B. Hjelm, J. Kilbourne, C. J. Arntzen, Q. Chen, and H. S. Mason. 2008. An efficient plant viral expression system generating orally immunogenic Norwalk virus-like particles. Vaccine26:1846-1854.","journal-title":"Vaccine"},{"key":"e_1_3_2_47_2","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1517\/13543784.7.3.437","volume":"7","year":"1998","unstructured":"Slade, H. B., M. L. Owens, M. A. Tomai, and R. L. Miller. 1998. Imiquimod 5% cream (Aldara). Expert Opin. Invest. Drugs7:437-449.","journal-title":"Expert Opin. Invest. Drugs"},{"key":"e_1_3_2_48_2","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1016\/j.vaccine.2003.09.052","volume":"22","year":"2004","unstructured":"Thomsen, L. L., P. Topley, M. G. Daly, S. J. Brett, and J. P. Tite. 2004. Imiquimod and resiquimod in a mouse model: adjuvants for DNA vaccination by particle-mediated immunotherapeutic delivery. Vaccine22:1799-1809.","journal-title":"Vaccine"},{"key":"e_1_3_2_49_2","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1006\/cimm.2000.1673","volume":"203","year":"2000","unstructured":"Tomai, M. A., L. M. Imbertson, T. L. Stanczak, L. T. Tygrett, and T. J. Waldschmidt. 2000. The immune response modifiers imiquimod and R-848 are potent activators of B lymphocytes. Cell. Immunol.203:55-65.","journal-title":"Cell. Immunol."},{"key":"e_1_3_2_50_2","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1586\/14760584.6.5.835","volume":"6","year":"2007","unstructured":"Tomai, M. A., R. L. Miller, K. E. Lipson, W. C. Kieper, I. E. Zarraga, and J. P. Vasilakos. 2007. Resiquimod and other immune response modifiers as vaccine adjuvants. Expert Rev. Vaccines6:835-847.","journal-title":"Expert Rev. Vaccines"},{"key":"e_1_3_2_51_2","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1007\/s00109-006-0084-y","volume":"84","year":"2006","unstructured":"Uematsu, S., and S. Akira. 2006. Toll-like receptors and innate immunity. J. Mol. Med.84:712-725.","journal-title":"J. Mol. Med."},{"key":"e_1_3_2_52_2","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1006\/cimm.2000.1689","volume":"204","year":"2000","unstructured":"Vasilakos, J. P., R. M. Smith, S. J. Gibson, J. M. Lindh, L. K. Pederson, M. J. Reiter, M. H. Smith, and M. A. Tomai. 2000. Adjuvant activities of immune response modifier R-848: comparison with CpG ODN. Cell. Immunol.204:64-74.","journal-title":"Cell. Immunol."},{"key":"e_1_3_2_53_2","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S1521-6616(03)00202-X","volume":"109","year":"2003","unstructured":"Verthelyi, D., and D. M. Klinman. 2003. Immunoregulatory activity of CpG oligonucleotides in humans and nonhuman primates. Clin. Immunol.109:64-71.","journal-title":"Clin. Immunol."},{"key":"e_1_3_2_54_2","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1006\/cimm.1998.1406","volume":"191","year":"1999","unstructured":"Wagner, T. L., C. L. Ahonen, A. M. Couture, S. J. Gibson, R. L. Miller, R. M. Smith, M. J. Reiter, J. P. Vasilakos, and M. A. Tomai. 1999. Modulation of TH1 and TH2 cytokine production with the immune response modifiers, R-848 and imiquimod. Cell. Immunol.191:10-19.","journal-title":"Cell. Immunol."},{"key":"e_1_3_2_55_2","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.antiviral.2004.07.002","volume":"64","year":"2004","unstructured":"Wu, J. J., D. B. Huang, and S. K. Tyring. 2004. Resiquimod: a new immune response modifier with potential as a vaccine adjuvant for Th1 immune responses. Antiviral Res.64:79-83.","journal-title":"Antiviral Res."},{"key":"e_1_3_2_56_2","doi-asserted-by":"crossref","first-page":"49","DOI":"10.2174\/1874285800802010049","volume":"2","year":"2008","unstructured":"Xagorari, A., and K. Chlichlia. 2008. Toll-like receptors and viruses: induction of innate antiviral immune responses. Open Microbiol. J.2:49-59.","journal-title":"Open Microbiol. J."},{"key":"e_1_3_2_57_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.01527-07"}],"container-title":["Clinical and Vaccine Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CVI.00230-10","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CVI.00230-10","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,31]],"date-time":"2024-03-31T16:42:02Z","timestamp":1711903322000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/CVI.00230-10"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12]]},"references-count":56,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["10.1128\/CVI.00230-10"],"URL":"https:\/\/doi.org\/10.1128\/cvi.00230-10","relation":{},"ISSN":["1556-6811","1556-679X"],"issn-type":[{"value":"1556-6811","type":"print"},{"value":"1556-679X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,12]]},"assertion":[{"value":"2010-06-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2010-10-09","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}